P180 Aetiology of Bronchiectasis in a Non-Specialist Service. How Does COPD Affect the Picture?: Abstract P180 Table 1

Abstract

Poster sessions A142Thorax 2012;67(Suppl 2):A1-A204Prescription refill data were used to calculate percentage adherence by dividing the amount collected by the amount prescribed, multiplied by 100. Participants were categorised as adherent (score≥80%) and non-adherent (score<80%) to inhaled antibiotics and other respiratory medicines using this method. Participants completed the modified Self-reported Medication-taking Scale for ACT (score 0-5; adherent score≥4, non-adherent score<4). Spirometry was performed according to ATS/ERS guidelines. Chi square tests were used for between group analyses. Results 75 participants were recruited: 24M/51F; mean (SD) age 64 (8) yrs; FEV 1 61 (25) % predicted. Sixty-four (85%) participants were prescribed colomycin, 11 (15%) were prescribed tobramycin, 68 (91%) were prescribed bronchodilators and 65 (87%) were prescribed inhaled corticosteroids. All participants were prescribed ACT; active cycle of breathing techniques (n=39, 53%) and Acapella ® (n=45, 61%) were most commonly prescribed. Eleven percent (16%) participants were adherent to all treatments. Fifty-two percent and 51% of participants were adherent to inhaled antibiotics and other respiratory medicines, respectively. Thirty-nine percent of participants were adherent to ACT. Adherence category varied significantly between inhaled antibiotics and other respiratory medicines (p=0.04), with 34% of participants being adherent to one treatment and not the other. Conclusion Patients with bronchiectasis patients infected with P. aeruginosa have a high burden of treatment. Only 11% of patients were adherent to all treatments, half were adherent to medicines and even fewer were adherent to ACT, indicating that patients make decisions about which treatments to use.

Aetiology of bronchiectasis in adults: A systematic literature review

“…Upon further review, 6201 abstracts or articles were rejected for meeting the study exclusion criteria (design not an observational study or no non‐cystic fibrosis bronchiectasis patients enrolled). Of the 306 full‐text articles reviewed at Level II screening, 54 reported on aetiologies of bronchiectasis . The reference lists of included studies were manually reviewed for identification of relevant articles that were not identified from the initial search.…”

“…The prevalence of the identified aetiologies ranged from 18% to 95%. Geographically, 62.5% of aetiologies ( n = 35) were reported in studies conducted in Europe, 14.3% ( n = 8) in Asia, six in Oceania (Australia), five in South America (Brazil), one in North America (USA) and one in Africa (Tunisia)…”